drugset
Drugs / CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
last change Sep 2026 re-read 3 minutes ago

CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine

Vaccine

Developed for
Her2-receptor negative breast cancer
Investigated by
Breast Cancer Alliance · United States Department of Defense · University of Washington

Trials 1

today NCT02157051 · Ph 1
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02157051 Jun 2015 → Nov 2022 overdue Her2-receptor negative breast cancer University of Washington Active not recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT02157051 ↗
Modality Vaccine “multiantigen deoxyribonucleic acid (DNA) plasmid-based vaccine” NCT02157051 ↗